Back to search results

Mobile Platform for Optimizing Wellness and Engagement in Recovery

This study is testing a mobile app designed to help people in recovery from opioid and alcohol use disorders. It's for individuals who are already receiving opioid agonist treatment (OAT), like buprenorphine or methadone, and also have alcohol use disorder. The study aims to see if using a digital app, which might offer rewards for healthy activities and abstinence, is practical and helpful. You would use one version of the app for six months. To join, you need to be between 19 and 63 years old, enrolled in Michigan Medicaid, and have regular access to a smartphone and internet. The main goals are to see how many people join, how well they use the app, and how many stay in the study.

Study design
This is an interventional pilot study with 50 participants. It is testing two different versions of a mobile app.
What's involved
You would use a version of the app for six months. This includes random saliva drug tests, breathalyzer tests, video selfies, and completing surveys.
Compensation
Participants in the Digital Contingency Management Intervention Arm may earn rewards on a debit card.
Follow-up
The study measures participant retention and adherence for 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07178990

Mobile Platform for Optimizing Wellness and Engagement in Recovery

Recruiting
NAAges 19–63InterventionalTreatment
University of Michigan
~50 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:Digital Contingency Management Intervention ArmDigital Wellness Arm

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Feasibility based on recruitment
Measured over Recruitment period 12 months
+3 more outcomes measured

Conditions

Opioid Agonist Treatment
Alcohol Use Disorder
Opioid Use Disorder

Explore related trials

Alcohol use disorderOpioid Use Disorder

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Lara Coughlin, PhD · PRINCIPAL_INVESTIGATOR · University of Michigan
  • Anne C Fernandez, PhD · PRINCIPAL_INVESTIGATOR · Rutgers University

Who to contact

Haley Stevens
[email protected]
734-764-9910
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must be enrolled in the Michigan Medicaid program
Opioid agonist treatment (OAT): Participants must have initiated OAT with buprenorphine or methadone
Participants must have an OAT prescription and Alcohol use disorder (AUD) based on self-report measure during screening
Participants must have regular access to a working smartphone and internet connection.
Participants must have a reliable mailing address to receive study supplies (e.g., salivary drug tests).

Exclusion

Primary Medicare Coverage: Individuals that are dual-eligible for Medicaid and Medicare and aged 65 or older, due to limited availability of Medicaid claims data for this group
Individuals that cannot voluntarily provide informed consent themselves for any reason, including legal incompetency
Individuals with substantial cognitive impairment that would interfere with study participation
Individuals unable to read or understand English
Individuals experiencing active suicidality or psychosis.
Individuals with a planned admission to residential treatment or incarceration during the study period.

What this trial measures

  • Feasibility based on recruitmentRecruitment period 12 months

    Recruitment: ≥60% of participants enrolled

  • Feasibility based on adherence6 months (during the Dynamicare program)

    Adherence: ≥50% of app-based, biochemically-verified tests completed in the digital CM condition.

  • Feasibility based on Retention6 months

    Retention: ≥70% of participants retained at 6 months

  • Acceptability of the intervention3-month after starting program

    Defined as \>70% of participants rating the intervention experience ≥ 4/5 on the Acceptability of Intervention Measure